SkinBioTherapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2016
Period Ending	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	2018 - 2016
Operating Revenue	0.16	0.13	0.07	-	-	-	Upgrade
Revenue	0.16	0.13	0.07	-	-	-	Upgrade
Revenue Growth (YoY)	24.54%	76.64%	-	-	-	-	Upgrade
Cost of Revenue	0.06	0.05	0.03	-	-	-	Upgrade
Gross Profit	0.1	0.09	0.05	-	-	-	Upgrade
Selling, General & Admin	2.4	2.15	2.17	0.99	0.98	0.65	Upgrade
Research & Development	0.73	0.93	0.86	0.51	0.64	0.71	Upgrade
Operating Expenses	3.14	3.08	3.03	1.5	1.62	1.36	Upgrade
Operating Income	-3.03	-3	-2.98	-1.5	-1.62	-1.36	Upgrade
Interest Expense	-0.01	-0.01	-0.01	-0	-	-	Upgrade
Pretax Income	-3.04	-3.01	-2.99	-1.5	-1.62	-1.36	Upgrade
Income Tax Expense	-0.16	-0.17	-0.2	-0.07	-0.12	-0.21	Upgrade
Net Income	-2.88	-2.84	-2.79	-1.43	-1.5	-1.15	Upgrade
Net Income to Common	-2.88	-2.84	-2.79	-1.43	-1.5	-1.15	Upgrade
Shares Outstanding (Basic)	175	165	157	147	128	122	Upgrade
Shares Outstanding (Diluted)	175	165	157	147	128	122	Upgrade
Shares Change (YoY)	11.47%	5.06%	6.87%	14.53%	4.95%	2.81%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.02	-0.01	-0.01	-0.01	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.02	-0.01	-0.01	-0.01	Upgrade
Free Cash Flow	-3.12	-2.73	-2.67	-1.56	-0.89	-1.44	Upgrade
Free Cash Flow Per Share	-0.02	-0.02	-0.02	-0.01	-0.01	-0.01	Upgrade
Gross Margin	62.90%	64.51%	60.64%	-	-	-	Upgrade
Operating Margin	-1877.21%	-2271.26%	-3988.83%	-	-	-	Upgrade
Profit Margin	-1784.72%	-2146.91%	-3735.37%	-	-	-	Upgrade
Free Cash Flow Margin	-1931.00%	-2071.02%	-3575.44%	-	-	-	Upgrade
EBITDA	-3	-2.99	-2.98	-1.5	-1.61	-1.36	Upgrade
D&A For EBITDA	0.04	0.01	0	0	0.01	0	Upgrade
EBIT	-3.03	-3	-2.98	-1.5	-1.62	-1.36	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.